Adhesion Barrier for Open Heart Surgery

A pivotal clinical trial to assess the efficacy of the new barrier, called Repel-CV, is being planned that will involve around 15 pediatric cardiac surgery centers. The trial will specifically address the effectiveness of Repel-CV to prevent and reduce adhesion formation in neonatal patients who require a staged series of procedures. The results of the trial will be used to obtain approval from the US Food and Drug Administration (FDA), which if received would represent the first such adhesion barrier approved by the agency.

The adhesion barrier was developed by Life Medical Sciences, Inc. (Oceanport, NJ), a biomaterials company engaged in the development and commercialization of innovative and cost-effective medical devices. The company intends to develop a broad range of bioresorbable polymer products to prevent or reduce postoperative adhesions.




Related Links:
Life Medical Sciences